Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.
Casey M. Cosgrove, MD
Advertisement
Articles by Casey M. Cosgrove, MD
Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.
Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.
Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.
Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Cosgrove on Selecting a PARP Inhibitor for Maintenance Therapy in Ovarian CancerPublished: November 12th 2019 | Updated:
Dr. Cosgrove on Retreatment With PARP Inhibitors in Ovarian CancerPublished: December 18th 2019 | Updated:
Dr. Cosgrove on the Approval of Niraparib in Advanced Ovarian CancerPublished: January 24th 2020 | Updated:
Dr. Cosgrove on the Utilization of PARP Inhibition in Ovarian CancerPublished: April 8th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5